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Background: Secondary resection of initially unresectable colorectal cancer liver metastases (CRLM)
can prolong survival. The added value of selective internal radiotherapy (SIRT) to downsize lesions for
resection is not known. This study evaluated the change in technical resectability of CRLM with the
addition of SIRT to FOLFOX-based chemotherapy.
Methods: Baseline and follow-up hepatic imaging of patients who received modified FOLFOX (mFOL-
FOX6: fluorouracil, leucovorin, oxaliplatin) chemotherapy with or without bevacizumab (control arm)
versus mFOLFOX6 (with or without bevacizumab) plus SIRT using yttrium-90 resin microspheres (SIRT
arm) in the phase III SIRFLOX trial were reviewed by three or five (of 14) expert hepatopancreatobiliary
surgeons for resectability. Reviewers were blinded to one another, treatment assignment, extrahepatic
disease status, and information on clinical and scanning time points. Technical resectability was defined
as at least 60 per cent of reviewers (3 of 5, or 2 of 3) assessing a patient’s liver metastases as surgically
removable.
Results: Some 472 patients were evaluable (SIRT, 244; control, 228). There was no significant baseline
difference in the proportion of technically resectable liver metastases between SIRT (29, 11⋅9 per cent)
and control (25, 11⋅0 per cent) arms (P = 0⋅775). At follow-up, significantly more patients in both arms
were deemed technically resectable compared with baseline: 159 of 472 (33⋅7 per cent) versus 54 of 472
(11⋅4 per cent) respectively (P =0⋅001). More patients were resectable in the SIRT than in the control
arm: 93 of 244 (38⋅1 per cent) versus 66 of 228 (28⋅9 per cent) respectively (P < 0⋅001).
Conclusion: Adding SIRT to chemotherapy may improve the resectability of unresectable CRLM.
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Introduction
An increasingly aggressive surgical approach in patients
with colorectal cancer liver metastases (CRLM) has
led to higher numbers of long-term survivors. How-
ever, 80–90 per cent of patients with CRLM are not
amenable to surgery at diagnosis1–4 and liver metastases
remain the principal site of fatal colorectal cancer5–8.
Secondary resection and/or thermal ablation of primarily
unresectable CRLM following systemic treatment may
prolong survival or be curative in some patients4,9–16.
However, there is uncertainty surrounding the best
treatment combination to achieve downsizing of the
metastatic lesions for resection, as few trials have specifi-
cally addressed this17. In the absence of a clear definition
of unresectability, effective treatments for downsizing of
metastatic liver tumours are difficult to evaluate objec-
tively. Many factors influence the decision to perform
these procedures, and studies focusing on secondary
resection/ablation after downsizing treatment have
used very heterogeneous inclusion criteria15,18,19. Few
studies on the effects of liver-directed therapy on the
resectability of CRLM have been undertaken20. Selec-
tive internal radiotherapy (SIRT) with yttrium-90 (90Y)
labelled microspheres is a liver-directed therapy that
could downsize tumours and render them amenable to
surgery20.
In the randomized SIRFLOX trial that compared
chemotherapy with chemotherapy plus a single SIRT
procedure in patients with CRLM deemed unresectable,
the secondary resection rate was low in both arms21.
It is possible that this reflects the presence of poor
prognostic features unrelated to the extent of liver
tumour involvement, such as extrahepatic disease or
patient co-morbidity, or the reluctance of surgeons
to operate on the liver following SIRT because of
safety concerns22. Hence, the secondary resection rate
in SIRFLOX does not provide information on how
resectability would have been affected by chemotherapy or
chemotherapy plus SIRT in patients otherwise suitable for
surgery.
SIRT has yielded encouraging tumour response rates in
uncontrolled or small-scale studies23. In SIRFLOX, the
tumour response rate in the liver was approximately 10
per cent higher in the SIRT than in the control arm.
Response to chemotherapy had good correlation with sec-
ondary resection rates in previous trials13,14, but some
patients may remain unresectable owing to the distribu-
tion of the CRLM. These aspects are poorly covered by
defined resectability criteria used in studies, making image
assessment by experienced hepatopancreatobiliary (HPB)
surgeons the most reliable tool with which to determine
resectability. This approach was first used in the CELIM
(Cetuximab in Neoadjuvant Treatment of Non-Resectable
Colorectal Liver Metastases) trial24, where a blinded surgi-
cal image review revealed that almost one-third of patients
who were enrolled because their metastases had been
deemed unresectable by local assessment were in fact con-
sidered candidates for resection on expert review. The pro-
portion of potentially resectable patients increased to 60
per cent after cetuximab-containing chemotherapy, making
CELIM the first study to prove objectively the principle of
‘conversion’ chemotherapy. To date, no such data exist for
interventional treatments such as SIRT that may play a role
in conversion of unresectable liver metastases to surgery,
and, therefore, this post hoc analysis of SIRFLOX data was
performed.
Methods
The REsect study, a retrospective analysis of the SIR-
FLOX study patient cohort, was designed to determine
the quasi-objective change in resectability of CRLM
from baseline to follow-up after first-line treatment with
mFOLFOX6 chemotherapy (oxaliplatin, folinic acid and
fluorouracil regimen) with or without bevacizumab (con-
trol arm) or mFOLFOX6 with or without bevacizumab
plus SIRT (SIRT arm) with 90Y-labelled resin micro-
spheres (SIR-Spheres®; Sirtex Medical, Sydney, New
South Wales, Australia).
As REsect relied on existing CT hepatic imaging data
from SIRFLOX and no new data were acquired for the
analysis, no formal ethics committee approval was needed.
The SIRFLOX study was conducted in accordance with the
Declaration of Helsinki, and approval was obtained from
the relevant institutional review boards for each participat-
ing centre. All patients had to provide written informed
consent. SIRFLOX had the ClinicalTrials.gov identifier
NCT00724503.
Patients
All patients who had received first-line treatment for
CRLM in the SIRFLOX study were eligible for inclu-
sion in the REsect study. Patients had to have evaluable
CT data at baseline and follow-up, and have received the
allocated treatment. For enrolment in SIRFLOX, patients
had to have histologically confirmed adenocarcinoma of
the colon or rectum, with or without the primary tumour
in situ, with proven liver-dominant metastatic disease.
Patients had to be chemotherapy-naive, have a WHO per-
formance status of 0–1, and a life expectancy of more
than 3 months. Predefined stratification factors included
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Excluded from REsect n=23
 Allocated treatment not received n=21
 Non-evaluable scan n=2
Excluded from REsect n=35
 Allocated treatment not received n=11
 Non-evaluable scan n=24
mFOLFOX6 (±bevacizumab)
n=263 (ITT population)
Included in REsect analysis
n=228
Included in REsect analysis
n=244
the presence of extrahepatic metastases (liver-only ver-
sus liver-dominant metastatic colorectal cancer), hepatic
tumour burden (25 per cent or less versus more than 25
per cent), intent to use bevacizumab, and treatment cen-
tre. The protocol for SIRFLOX, including full details
of inclusion and exclusion criteria, has been published
previously25.
Treatment and assessment in the SIRFLOX study
Patients were randomized in a 1 : 1 ratio to treatment with
an mFOLFOX6 regimen alone or to mFOLFOX6 plus
SIRT with 90Y-labelled resin microspheres25. Chemother-
apy was continued until disease progression. Patients could
receive bevacizumab from cycle 1 in the control arm and
from cycle 4 onwards in the SIRT arm.
Patients in the SIRT arm had baseline hepatic angiog-
raphy and a liver-to-lung breakthrough nuclear medicine
scan to assess suitability to receive SIRT25. The patient’s
body surface area, percentage tumour involvement, and
magnitude of liver-to-lung shunting were used to deter-
mine the activity (GBq) administered. SIRT was given in a
single procedure on day 3–4 of cycle 1 or cycle 2 of mFOL-
FOX6 treatment.
Patients were assessed by CT every 8–12 weeks until
hepatic progression. Other follow-up assessments included
clinical assessment25 and suitability for liver resection, at
every CT time point. All patients were followed up until
death, or to the end of the study.
Blinded review of CT scans in REsect
A pool of 14 HPB surgeons were recruited to perform
the blinded review. All reviewers viewed a training video
(Video S1, supporting information) to ensure consistency in
reading the scans. The criterion for resectability was that
resection of all visible lesions, with negative margins and
a sufficient future liver remnant (FLR) size, was feasible.
Baseline and best response follow-up imaging of 100 ran-
domly selected patients were presented independently to
five HPB surgeons to determine the pooled interobserver
agreement and validate the analysis. This initial series of
assessments was designed to demonstrate the feasibility
of the study methodology. The assessments showed good
pooled interobserver agreement and provided the ratio-
nale for proceeding with three reviewers per case for the
remainder of cases.
All reviewers were blinded to clinical data, extent of extra-
hepatic disease, study arm assignment, and one another’s
assessments. To ensure that assessment was not biased by
a reviewer’s expectations on changes in resectability after
treatment, reviewers were also blinded to the timing of CT
(baseline versus follow-up). As the objective was to assess
the change in technical resectability of liver metastases,
reviewers were explicitly instructed to ignore any patient
features other than the extent of liver lesions that may have
been visible on the CT scan (such as extrahepatic metas-
tases), even if these might affect the decision for, or against,
surgery in real life. A patient was deemed to be resectable
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Table 1 Baseline characteristics of patients eligible for the REsect study
Control arm (n = 228) SIRT arm (n = 244) P¶
Age (years)* 62⋅6(10⋅9) 61⋅8(10⋅5) 0⋅484#
Sex ratio (M : F) 154 : 74 163 : 81 0⋅922
Body surface area (m2)* 1⋅87(0⋅21) 1⋅87(0⋅22) 0⋅884#
Estimated tumour burden (%)* 17⋅6 (15⋅3)† 18⋅3 (16⋅6)† 0⋅637#
Extrahepatic metastasis 91 (39⋅9) 99 (40⋅6) 0⋅925
Hepatic tumour burden (%) 0⋅416
≤25 166 (72⋅8)† 169 (69⋅3)†
>25 61 (26⋅8)† 74 (30⋅3)†
Primary tumour in situ 103 (45⋅2) 108 (44⋅3) 0⋅854
Hepatic miliary disease‡ 89 (39⋅0) 94 (38⋅5) 0⋅925
Side of primary tumour 0⋅100
Left 177 (77⋅6) 169 (69⋅3)
Right 46 (20⋅2) 68 (27⋅9)
Both or unknown 5 (2⋅2) 7 (2⋅9)
WHO performance status 0⋅923
0 149 (65⋅4) 160 (65⋅8)
1 79 (34⋅6) 83 (34⋅2)
Missing 0 1
Bevacizumab§ 133 (58⋅3) 122 (50⋅0) 0⋅079
Values in parentheses are percentages unless indicated otherwise; *values are mean(s.d.). †Data unknown for one patient in each arm. ‡Defined as at least 15
metastases, with reason to assume the patient would remain unresectable after treatment. §Patients who received bevacizumab before disease progression.
SIRT, selective internal radiotherapy; n.d., not done. ¶Fisher’s exact test, except #t test.
Table 2 Baseline characteristics of patients eligible for the REsect study, stratified by absence or presence of miliary disease
No miliary disease (n = 289) Miliary disease (n = 183)
Control arm (n = 139) SIRT arm (n = 150) P‡ Control arm (n = 89) SIRT arm (n = 94) P‡
Age (years)* 63⋅2(11⋅0) 63⋅0(10⋅7) 0⋅885§ 61⋅6(10⋅8) 60⋅0(10⋅1) 0⋅330§
Sex ratio (M : F) 90 : 49 96 : 54 0⋅903 64 : 25 67 : 27 1⋅000
Body surface area (m2)* 1⋅87(0⋅22) 1⋅86(0⋅21) 0⋅905§ 1⋅89(0⋅19) 1⋅89(0⋅22) 0⋅941§
Estimated tumour burden (%)* 13⋅0(14⋅1)† 12⋅9(14⋅9)† 0⋅952§ 24⋅8(14⋅5) 27⋅0(15⋅6) 0⋅941§
Extrahepatic metastasis 54 (38⋅8) 56 (37⋅3) 0⋅875 37 (42) 43 (46) 0⋅340
Hepatic tumour burden (%)
≤25 116 (84⋅1)† 124 (83⋅2)† 0⋅875 50 (56) 45 (48) 0⋅655
>25 22 (15⋅9)† 25 (16⋅8)† 39 (44) 49 (52)
1 1
Primary tumour in situ 53 (38⋅1) 57 (38⋅0) 1⋅000 50 (56) 51 (54) 0⋅882
Side of primary tumour
Left 110 (79⋅1) 100 (66⋅7) 67 (75) 69 (73) 0⋅560
Right 27 (19⋅4) 45 (30⋅0) 19 (21) 23 (24)
Both or unknown 2 (1⋅4) 5 (3⋅3) 3 (3) 2 (2)
WHO performance status
0 95 (68⋅3) 108 (72⋅5) 0⋅073 54 (61) 52 (55) 0⋅549
1 44 (31⋅7) 41 (27⋅5) 35 (39) 42 (45)
Missing 0 1 0 0
Values in parentheses are percentages unless indicated otherwise; *values are mean(s.d.). †Data unknown for one patient in each arm. SIRT, selective internal
radiotherapy. ‡Fisher’s exact test, except §t test.
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Percentage agreement on resectability or unresectability in a,b control and c,d selective internal radiotherapy (SIRT) arms at a,c baseline and b,d follow-up.
The dotted lines denote the 60 per cent threshold of agreement by the surgical review panel on resectability or unresectability.
or unresectable by majority agreement (3 of 5, or 2 of 3
surgeons: at least 60 per cent).
Objectives of REsect
The primary objective was to determine the change in
technical resectability of all liver lesions between baseline
and time of best treatment response in the liver (defined as
the deepest response (nadir) when the sum of the diameters
of all hepatic target lesions was lowest).
Subanalyses stratified by the presence or absence of mil-
iary disease in the liver (defined as at least 15 metas-
tases, with reason to assume the patient would remain
unresectable after treatment) and by hepatic tumour bur-
den (25 per cent or less or more than 25 per cent) were
performed.
Statistical analysis
All statistical analysis presented here was preplanned. The
analysis was performed on an evaluable population that was
a subset of the SIRFLOX per protocol population, defined
as all patients with evaluable baseline and follow-up CT
results who had received allocated treatment. Analyses
from the statistical analysis plan are not presented in their
entirety owing to space constraints. Descriptive statistics
are provided for patient and disease characteristics at
baseline. Change in resectability before and after treat-
ment was tested with the McNemar test, with matched
pairs. Agreement based on votes each at baseline and at
the time of best response was reported using percentage
agreement. Fisher’s exact test was used for all comparisons
except age, body surface area and tumour burden (t test). A
significance level of P < 0⋅050 was used in all comparisons.
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Fig. 3 Resectability of colorectal liver metastases
10
a  Whole cohort b  Patients deemed unresectable at baseline
c  Hepatic tumour burden ≤25% d  Hepatic tumour burden >25%









































































































































































Baseline and follow-up resectability rates in a the whole cohort; b patients deemed unresectable at baseline; c patients with a hepatic tumour burden of 25
per cent or less; d patients with a hepatic tumour burden greater than 25 per cent; e patients without hepatic miliary disease; f patients with hepatic miliary
disease.
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Results
SIRFLOX recruited 530 patients (263 in the control
and 267 in the SIRT arm)21. Of these, 472 patients had
evaluable baseline and follow-up imaging, and received
the allocated treatment (control, 228; SIRT, 244), form-
ing the population for this analysis (Fig. 1). The median
length of follow-up was 23⋅5 months. Baseline character-
istics were similar for patients in the two treatment arms
(Tables 1 and 2).
Among the 100 patients reviewed by five surgeons, agree-
ment on resectability/unresectability was 92⋅1 per cent at
baseline and 86⋅1 per cent at follow-up. In the study pop-
ulation as a whole, the agreement between reviewers was
100 per cent for 80⋅4 per cent of patients deemed to have
unresectable disease at baseline and around 64⋅8 per cent at
follow-up. In each treatment arm at baseline and follow-up,
the agreement between the surgeons was 100 per cent for
41⋅5 per cent of the patients deemed resectable and 80 per
cent (4 of 5 reviewers), 60 per cent (3 of 5 reviewers) or 67
per cent (2 of 3 reviewers) for the remainder (Fig. 2).
At baseline there was no statistically significant differ-
ence in the technical resectability rate of liver metastases
between the SIRT and control arms (11⋅9 versus 11⋅0 per
cent respectively; P = 0⋅775) (Fig. 3a). At follow-up, the
technical resectability rate increased significantly in both
arms (SIRT: 38⋅1 (95 per cent c.i. 32⋅0 to 45⋅0) per cent,
P < 0⋅001; control: 28⋅9 (23⋅0 to 35⋅0) per cent, P < 0⋅001).
The difference in resectability between SIRT and control
arms at follow-up was also statistically significant (relative
risk 1⋅25, 95 per cent c.i. 1⋅10 to 1⋅54; P < 0⋅001) (Fig. 3a).
Of patients in the control and SIRT arms deemed unre-
sectable at baseline, 46 of 203 (22⋅7 per cent) and 67 of
215 (31⋅2 per cent) respectively, were converted to techni-
cal resectability at follow-up (P < 0⋅001) (Fig. 3b).
At baseline, in patients with an initial hepatic tumour bur-
den of 25 per cent or less, there was no significant differ-
ence in the technical resectability rate of liver metastases
between the two treatment arms (P = 0⋅551) (Fig. 3c). In
both arms the increase in technical resectability from base-
line to follow-up tended to be more pronounced in this
population compared with the full data set (SIRT: 49⋅4
versus 17⋅1 per cent, P < 0⋅001; control: 34⋅7 versus 14⋅4
per cent, P < 0⋅001), and significantly more patients in the
SIRT arm with a tumour burden of 25 per cent or less
had technically resectable liver metastases at follow-up than
those in the control arm (P = 0⋅008) (Fig. 3c). At follow-up,
few patients in either arm with an initial tumour burden
greater than 25 per cent were deemed to have technically
resectable liver metastases, with no significant difference
between the control and SIRT arms (13 versus 12 per cent
respectively; P = 1⋅000) (Fig. 3d).
Table 3 Observed resections in SIRFLOX study versus




Resected 40 30 70
Unresected 119 283 402
Total 159 313 472
In patients without miliary disease, the increase in tech-
nical resectability rate from baseline to follow-up tended
to be more pronounced in both treatment arms compared
with the full data set (SIRT: 54⋅0 versus 19⋅3 per cent,
P < 0⋅001; control: 45⋅3 versus 18⋅0 per cent, P < 0⋅001).
At follow-up, a greater proportion of patients without mil-
iary disease in the SIRT arm (81 of 150, 54⋅0 per cent) had
resectable liver metastases compared with that in the con-
trol arm (63 of 139, 45⋅3 per cent), but the difference was
not statistically significant (P = 0⋅158) (Fig. 3e). Surpris-
ingly, three of 89 patients (3 per cent) with miliary disease
in the control arm and 12 of 94 (13 per cent) in the SIRT
arm were considered to have resectable lesions at follow-up
(P = 0⋅029) (Fig. 3f ).
In the SIRFLOX study, 70 patients had a resection,
some in combination with other local procedures or pre-
operative hepatic hypertrophy induction (SIRT, 36; con-
trol, 34). Forty of these patients were also classified in the
REsect study as having technically resectable disease (25
SIRT, 15 control), and 30 patients (11 SIRT, 19 control)
as having unresectable disease (Table 3). All 30 of these
patients were deemed to be candidates for complete hep-
atic tumour clearance through a combination of metastas-
ectomy and one or more additional procedures (such as
thermal ablation or preoperative induction of parenchymal
hypertrophy).
Discussion
REsect showed that in both treatment arms of the SIR-
FLOX study higher numbers were deemed to be techni-
cally resectable after treatment than at baseline. Moreover,
the addition of SIRT to the FOLFOX-based chemother-
apy regimen increased the technical resectability rate of
metastatic liver lesions at follow-up.
However, in the SIRFLOX study, as in studies investi-
gating different chemotherapy regimens in patients not
selected for potential secondary resectability26,27, there was
no difference between treatment arms in the rate of liver
resection21. In addition, SIRFLOX did not demonstrate
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any difference in progression-free survival at any site
between treatment arms. It has been suggested that inad-
equate patient selection has been partly responsible for
these negative results. Patients whose tumours have spread
far beyond oligometastatic liver disease may not derive
any survival benefit from liver-directed treatment, whereas
benefit may be obtained in patients with earlier disease
stages28.
Several reasons may explain the difference between
the actual resection rates in SIRFLOX and the technical
resectability rate determined in this blinded analysis. Rates
of resection are influenced by a range of different factors,
such as a patient’s overall fitness to undergo surgery, access
to a specialized hepatobiliary surgical centre, presence
and extent of concomitant extrahepatic disease, and the
surgeon’s general attitude and experience. This has also
been reported in other studies29, and was seen here. With
these factors in mind, many patients in the SIRFLOX
study may not have been considered for surgical resection
owing to the presence of extrahepatic disease (40 per cent
of enrolled patients had extrahepatic metastases and 45
per cent had a primary tumour in situ). Moreover, the
reluctance of surgeons to operate on livers treated with
90Y-labelled resin microspheres, owing to uncertainties
over the safety of such an approach, may also have reduced
the resection rate in the SIRT arm of SIRFLOX. Recently
published data30 have demonstrated that mortality and
complication rates in patients undergoing liver surgery
after SIRT appeared acceptable given the risk profile
of those particular patients; although further data are
needed, these results may reassure physicians regarding
the feasibility of this approach.
The criterion for resectability in REsect was that the
expert HPB surgeons deemed the resection of all visible
lesions to be feasible, with negative margins and sufficient
FLR size. It is well established, and recommended in treat-
ment guidelines, that the resectability of liver metastases
should be assessed by surgeons with extensive experience in
HPB surgery. HPB surgeons generally assess more patients
as resectable than general surgeons or surgeons from other
specialties31,32. This is also why, in studies focusing on
chemotherapy for unresectable CRLM, the reported rates
of conversion to resectability are extremely heterogeneous.
The addition of SIRT to chemotherapy improved the tech-
nical resectability rate in the subgroup of patients with a
hepatic tumour burden of 25 per cent or less, but not in
those with a greater tumour burden. The cutoff of 25 per
cent for tumour burden may therefore be useful for select-
ing patients likely to derive benefit from the addition of
SIRT in terms of potential secondary resectability of their
liver disease.
A blinded retrospective review of the CELIM trial scans
gave similar results to the present study. In the CELIM
trial, patients with metastatic colorectal cancer deemed
unresectable at baseline by the treating institution received
cetuximab with either FOLFOX or FOLFIRI (folinic
acid, fluorouracil and irinotecan); the resectability rate, by
blinded surgical assessment, increased from 32 per cent at
baseline to 60 per cent after treatment24. Despite higher
objective tumour response rates in the SIRFLOX study
(68⋅8–78⋅7 per cent) than in CELIM (57–68 per cent),
resectability rates were higher in CELIM. Population dif-
ferences between these trials probably account for the dif-
ferences: CELIM focused specifically on conversion to
secondary resectability in a potentially curative treatment
approach, whereas patients in SIRFLOX were not selected
for potential for secondary resectability21.
The limitations of this analysis are those inherent to a
post hoc analysis. For example, SIRFLOX may not have
been powered adequately for such an analysis. Although
the blinded approach is useful to remove potential bias,
it also obscures clinically important reasons why resec-
tion was not performed in specific patients. No attempt
was made to correlate the theoretical technical resectabil-
ity, in the judgement of the panel of HPB surgeons, with
any resections performed in patients who participated in
the study. However, REsect was designed bearing this in
mind, and factors precluding resection other than techni-
cal unresectability were disregarded intentionally, as the
aim was to evaluate how SIRT might have performed
as a conversion treatment in patients who were potential
candidates for resection. Given that no formal hypothe-
sis testing was undertaken due to the post hoc nature of
the analysis, demonstration of clinical significance requires
additional validation in an adequately powered sample
population.
Nevertheless, the present results provide a rationale
for considering the addition of SIRT to FOLFOX-based
chemotherapy (with or without bevacizumab) in such
patients, and this approach should be tested in a prospec-
tive trial focusing on this population of patients with
non-diffuse, technically unresectable, liver-only metastatic
colorectal cancer who are fit for surgery. The protocol for
this trial, with secondary resection rate and disease-free
survival following resection as co-primary endpoints, is
currently in development.
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